# EDGAR Filing Document

**Accession Number:** 0001382574
**File Stem:** 0001493152-25-016882
**Filing Date:** 2025-10
**Character Count:** 13975
**Document Hash:** a728726aab6dbce52ff9edb9b7b4304f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-016882.hdr.sgml**: 20251003

**ACCESSION NUMBER**: 0001493152-25-016882

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251003

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251003

**DATE AS OF CHANGE**: 20251003

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scienture Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001382574
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39199
- **FILM NUMBER:** 251374662

**BUSINESS ADDRESS:**
- **STREET 1:** 20 AUSTIN BLVD.
- **CITY:** COMMACK
- **STATE:** NY
- **ZIP:** 11725
- **BUSINESS PHONE:** (800) 261 0281

**MAIL ADDRESS:**
- **STREET 1:** 20 AUSTIN BLVD.
- **CITY:** COMMACK
- **STATE:** NY
- **ZIP:** 11725

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRxADE HEALTH, INC
- **DATE OF NAME CHANGE:** 20210602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRXADE GROUP, INC.
- **DATE OF NAME CHANGE:** 20140207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCELLINK INTERNATIONAL INC.
- **DATE OF NAME CHANGE:** 20081230

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 3, 2025**

**Scienture Holdings, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39199** | **46-3673928** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File No.) | (I.R.S. Employer<br> Identification No.) |

---

**20 Austin Blvd.**

**Commack, NY 11725**

(Address of Principal Executive Offices)

**(631) 670-6039**

(Registrant's Telephone Number)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.00001 per share** | **SCNX** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

As previously disclosed, Scienture Holdings, Inc. (the "***Company***") issued 10% original issue discount secured convertible debentures (the "***Debentures***") to Arena Finance Markets, LP and Arena Special Opportunities III LP (the "***Arena Investors***") on November 25, 2024.

On October 3, 2025, the Company entered into a letter agreement (the "***Agreement***") with the Arena Investors whereby the Company and the Arena Investors agreed to amend Section 4(b) of the Debentures. Specifically, the Company and the Arena Investors agreed to revise the conversion price of the Debentures to $2.4861 per share. In addition, each of the Arena Investors agreed to convert the remaining amounts owed by the Company under the Debentures into shares of the Company's common stock, par value $0.00001 per share (the "***Common Stock***") in accordance with the revised terms of the Debentures (the "***Full Conversion***").

Pursuant to the Agreement, upon the Full Conversion, automatically and without any further action on the part of the Company or the Arena Investors: (i) all Obligations (as defined in the Security Agreement dated November 25, 2024, by and among the Company and the Arena Investors) under the Transaction Documents (as defined in the Securities Purchase Agreement dated November 22, 2024, by and among the Company and the Arena Investors (the "***Purchase Agreement***")) will be deemed paid and will be automatically and irrevocably released, satisfied and discharged in full (except those obligations of the Company under Section 5.10 of the Purchase Agreement and Section 7 of the Registration Rights Agreement dated November 25, 2024, by and among the Company and the Arena Investors); (ii) the Debentures and all other Transaction Documents will be terminated; (iii) all security interests, pledges and other liens of every type at any time granted to or held by the Arena Investors as security for the Obligations or under any Transaction Document will be terminated and automatically and irrevocably released without further action by the Arena Investors; and (iv) neither of the Arena Investors will have any obligation to make any credit extensions or financial accommodations to the Company or any other obligations, duties, or responsibilities in connection therewith.

The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated herein in its entirety by reference.

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Letter Agreement dated October 2, 2025, by and among the Company, Arena Finance Markets, LP, and Arena Special Opportunities III LP](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SCIENTURE HOLDINGS, INC.** | **SCIENTURE HOLDINGS, INC.** |
|  | By: | */s/ Dr. Narasimhan Mani* |
|  |  | Dr. Narasimhan Mani |
|  |  | Co-Chief Executive Officer |
| Date: October 3, 2025 |  |  |

---

## Exhibit 10.1

**Exhibit 10.1**

October 3, 2025

Scienture Holdings, Inc.

20 Austin Blvd.

Commack, NY 11725

Attention: Dr. Narasimhan Mani, Co-Chief Executive Officer

Email: nmani@scienture.com

With a copy to:

Dykema Gossett PLLC

111 E Kilbourn Avenue, Suite 1050

Milwaukee, Wisconsin 53202

Attention: Kate Bechen<br> Email: KBechen@dykema.com

---

| | |
|:---|:---|
| **Re:** | **Acknowledgement of Satisfaction – 10% Original Issue Discount Secured Debentures** |

---

Dear Dr. Mani:

Reference is made to that certain Securities Purchase Agreement by and between Scienture Holdings, Inc. (the "**Company**"), and the purchasers party thereto, dated November 22, 2024 (the "**Purchase Agreement**"), and the 10% original issue discount secured debentures (the "**Debentures**") issued on November 25, 2024, pursuant to the terms thereof, to each of Arena Finance Markets, LP ("**AFM**") and Arena Special Opportunities III LP ("**ASO**", and together with AFM, the "**Holders**"). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement or Debentures, as applicable.

The Company and the Holders agree that it is in the best interest of the parties to satisfy all obligations under the Debentures via their conversion in accordance with their terms. In this regard, the Company and AFM agree that upon the conversion of $454,647.03 into shares of Common Stock, in accordance with terms of the Debenture issued to AFM, such Debenture shall be deemed paid in full and otherwise satisfied and the Company and ASO agree that upon the conversion of $104,718.89 into shares of Common Stock, in accordance with terms of the Debenture issued to ASO, such Debenture shall be deemed paid in full and otherwise satisfied. For purposes of this letter, the conversion in full of the foregoing amounts under the Debentures shall be referred to as the "**Full Conversion.**"

In furtherance of the foregoing, each of the Company and the Holders agree that in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Debenture shall be amended to delete Section 4(b) thereof in its entirety and replace the same with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Conversion Price</u>. The conversion price of this Debenture in effect as of any Conversion Date shall
 be a price per share of Common Stock equal to $2.4861 (the " <u>Conversion Price</u> ").

Each Holder agrees that, promptly following execution of this letter, the Company shall file a Current Report on Form 8-K disclosing the matters set forth in this letter. Subject to the beneficial ownership limitations set forth in Section 4(d) of each Debenture, each Holder will submit conversion notices as promptly as is commercially reasonable to effect the Full Conversion.

Effective immediately upon the Full Conversion, automatically and without any further action on the party of the Company or the Holders, (i) all Obligations (as defined in the Security Agreement) under the Transaction Documents shall be deemed paid and shall be automatically and irrevocably released, satisfied and discharged in full (except those obligations of the Company under Section 5.10 of the Purchase Agreement and Section 7 of the Registration Rights Agreement entered into between the Company and the Holders, on November 25, 2024); (ii) the Debentures and all other Transaction Documents shall be automatically terminated; (iii) all security interests, pledges and other liens of every type at any time granted to or held by a Holder as security for the Obligations or under any Transaction Document shall be terminated and automatically and irrevocably released without further action by a Holder; and (iv) neither Holder will have any obligation to make any credit extensions or financial accommodations to the Company or any other obligations, duties, or responsibilities in connection therewith.

Each Holder authorizes the Company, or any other party on behalf of the Company, upon the Full Conversion, to prepare and file any UCC-3 Termination Statements or other documents reasonably necessary or desirable to evidence the release of the Holder's security interests in any of the property or assets of the Company or Company Sub and in any third party and any of such third party's property or assets that guarantied the Obligations or provided collateral security therefor. Upon the Full Conversion, each Holder shall promptly (i) deliver to such third party such termination notices relating to any deposit or securities account control agreements, intellectual property security agreements, landlord waivers or collateral access agreements or any other notices or documents terminating or evidencing the termination of a Holder's security interest arising under the Transaction Documents reasonably requested by the Company at the Company's expense, and (ii) if applicable, return any pledged instruments and/or securities and/or other possessory collateral of the Company in the Holder's (or its agent's) possession to the Company. From and after the satisfaction of the Full Conversion, the Holder further agrees promptly to procure, deliver, or execute and deliver to the Company, from time to time, all further releases not specified above, certificates, instruments, and documents as may be reasonably requested by the Company or which are reasonably required or desirable to evidence the consummation of the payoff and releases contemplated hereby, in each case, at the expense of the Company.

This letter (i) may be executed in multiple counterparts and by electronic signature, each of which shall be deemed an original and all of which together shall constitute one instrument, and (ii) shall be governed by and construed in accordance with the Laws of the State of Delaware, without reference to principles of conflict of laws or choice of laws.

[*Signature Page Follows*]

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| <u>HOLDERS</u>: | <u>HOLDERS</u>: |
| **Arena Finance Markets, LP** | **Arena Finance Markets, LP** |
| By: | */s/ Lawrence Cutler*  |
| Name: | Lawrence Cutler |
| Title: | Authorized Signatory |
| **Arena Special Opportunities III LP** | **Arena Special Opportunities III LP** |
| By: | */s/ Lawrence Cutler* |
| Name: | Lawrence Cutler |
| Title: | Authorized Signatory |

---

---

| | |
|:---|:---|
| **<u>ACCEPTED AND AGREED</u>**: | **<u>ACCEPTED AND AGREED</u>**: |
| <u>COMPANY</u>: | <u>COMPANY</u>: |
| **SCIENTURE HOLDINGS, INC.** | **SCIENTURE HOLDINGS, INC.** |
| By: | */s/ Dr. Narasimhan Mani* |
| Name: | Dr. Narasimhan Mani |
| Title: | Co-Chief Executive Officer and President |

---